MA32588B1 - Derives azotes de la pancratistatine - Google Patents

Derives azotes de la pancratistatine

Info

Publication number
MA32588B1
MA32588B1 MA33648A MA33648A MA32588B1 MA 32588 B1 MA32588 B1 MA 32588B1 MA 33648 A MA33648 A MA 33648A MA 33648 A MA33648 A MA 33648A MA 32588 B1 MA32588 B1 MA 32588B1
Authority
MA
Morocco
Prior art keywords
pancratistatin
nitrogen derivatives
relates
derivatives
nitrogen
Prior art date
Application number
MA33648A
Other languages
Arabic (ar)
English (en)
Inventor
Frédéric Marion
Jean-Philippe Annereau
Jacques Fahy
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32588(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32588B1 publication Critical patent/MA32588B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des dérivés azotés de narciclasine et de pancratistatine représentés par la formule générale suivante (i) ainsi que leurs sels pharmaceutiquement acceptables. La présente invention concerne également l'utilisation de ces composés pour le traitement du cancer ainsi qu'un procédé permettant de les préparer.
MA33648A 2008-07-28 2011-02-28 Derives azotes de la pancratistatine MA32588B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0855161A FR2934266B1 (fr) 2008-07-28 2008-07-28 Derives azotes de la pancratistatine
PCT/EP2009/059715 WO2010012714A1 (fr) 2008-07-28 2009-07-28 Dérivés azotés de pancratistatine

Publications (1)

Publication Number Publication Date
MA32588B1 true MA32588B1 (fr) 2011-08-01

Family

ID=40394438

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33648A MA32588B1 (fr) 2008-07-28 2011-02-28 Derives azotes de la pancratistatine

Country Status (24)

Country Link
US (2) US8415348B2 (fr)
EP (1) EP2324031B1 (fr)
JP (1) JP5666442B2 (fr)
KR (1) KR20110036842A (fr)
CN (1) CN102137867A (fr)
AR (1) AR072880A1 (fr)
AU (1) AU2009275929B2 (fr)
BR (1) BRPI0916716A2 (fr)
CA (1) CA2731901A1 (fr)
CL (1) CL2011000168A1 (fr)
CO (1) CO6341557A2 (fr)
ES (1) ES2584165T3 (fr)
FR (1) FR2934266B1 (fr)
GE (1) GEP20135818B (fr)
HU (1) HUE028098T2 (fr)
IL (1) IL210868A0 (fr)
MA (1) MA32588B1 (fr)
MX (1) MX2011000956A (fr)
NZ (1) NZ591298A (fr)
PL (1) PL2324031T3 (fr)
RU (1) RU2011106570A (fr)
TW (1) TW201011031A (fr)
WO (1) WO2010012714A1 (fr)
ZA (1) ZA201101426B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376498A4 (fr) * 2008-12-18 2013-01-09 Univ Brock Nouveaux analogues substitués en c 1 de la pancratistatine et de la 7 désoxypancratistatine et leurs procédés de préparation
CN101805384B (zh) * 2010-04-26 2014-08-20 江苏省中国科学院植物研究所 一种新石蒜异喹诺酮类生物碱及其制备方法和用途
GB2498539A (en) * 2012-01-18 2013-07-24 Renesas Mobile Corp Base station assisted asymmetric device-to-device communications
CN106543194A (zh) * 2015-09-22 2017-03-29 孙青* 水仙环素衍生物及其制备与在制备抗肿瘤药物中的应用
CN105481880B (zh) * 2015-12-01 2017-07-14 哈尔滨凝昇科技有限公司 一种新化合物及其应用
CN115894507B (zh) * 2022-11-01 2024-06-07 昆明医科大学 (+)-水鬼蕉碱的合成方法及其应用
CN115677714B (zh) * 2022-11-01 2024-06-11 昆明医科大学 (+)-水鬼蕉碱制备中的中间体及其应用
WO2026054480A1 (fr) * 2024-09-04 2026-03-12 국립암센터 Composition pour la prévention ou le traitement du cancer comprenant du cisplatine et de la narciclasine ou un analogue de celle-ci

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985436A (en) * 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
US5529989A (en) * 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
US7462609B2 (en) * 2002-12-09 2008-12-09 Arizona Board Of Regents Narcistatin prodrugs
WO2005007084A2 (fr) * 2003-06-20 2005-01-27 Arizona Board Of Regents A Body Corporate Of The State Of Arizone, Acting For And On Behalf Of Arizona State University Promedicaments de phosphate cyclique de pancratistatine et promedicaments de phosphate cyclique de phenpanstatine
EP1720552A2 (fr) 2004-03-05 2006-11-15 Arizona Board of Regents, acting for and on behalf of Arizona State University Methodes pour traiter des maladies inflammatoires et auto-immunes
US7709643B2 (en) * 2005-01-14 2010-05-04 Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University Synthesis of sodium narcistatin and related compounds
CA2665605A1 (fr) * 2006-10-13 2008-04-17 Unibioscreen Sa Nouveaux derives d'isocarbostyryl alcaloide
EP2376498A4 (fr) * 2008-12-18 2013-01-09 Univ Brock Nouveaux analogues substitués en c 1 de la pancratistatine et de la 7 désoxypancratistatine et leurs procédés de préparation

Also Published As

Publication number Publication date
JP5666442B2 (ja) 2015-02-12
MX2011000956A (es) 2011-07-29
GEP20135818B (en) 2013-05-10
PL2324031T3 (pl) 2016-11-30
AU2009275929A1 (en) 2010-02-04
US8697064B2 (en) 2014-04-15
EP2324031A1 (fr) 2011-05-25
ES2584165T3 (es) 2016-09-26
IL210868A0 (en) 2011-04-28
CO6341557A2 (es) 2011-11-21
JP2011529097A (ja) 2011-12-01
RU2011106570A (ru) 2012-09-10
HUE028098T2 (en) 2016-11-28
TW201011031A (en) 2010-03-16
US20130121986A1 (en) 2013-05-16
EP2324031B1 (fr) 2016-05-04
US8415348B2 (en) 2013-04-09
FR2934266B1 (fr) 2010-09-17
CL2011000168A1 (es) 2011-07-15
WO2010012714A1 (fr) 2010-02-04
US20110123516A1 (en) 2011-05-26
FR2934266A1 (fr) 2010-01-29
CA2731901A1 (fr) 2010-02-04
KR20110036842A (ko) 2011-04-11
AR072880A1 (es) 2010-09-29
ZA201101426B (en) 2011-10-26
BRPI0916716A2 (pt) 2015-11-10
AU2009275929B2 (en) 2013-06-20
NZ591298A (en) 2011-12-22
CN102137867A (zh) 2011-07-27

Similar Documents

Publication Publication Date Title
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
CY1116989T1 (el) C-28 αμινες c-3 τροποποιημενων παραγωγων βετουλινικου οξεος ως αναστολεις hiv ωριμανσης
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
NZ627274A (en) Anesthetic compounds and related methods of use
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
PH12014500386A1 (en) Combination treatment for hepatitis c
WO2011123946A8 (fr) Inhibiteurs de kinases et procédé de traitement du cancer utilisant ceux-ci
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
IN2012DN03182A (fr)
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
PH12015501088A1 (en) Dimeric compounds